Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety of Estrogens in Lupus: Hormone Replacement Therapy
This study has been terminated.
Study NCT00000419   Information provided by New York University School of Medicine

First Received on November 3, 1999.   Last Updated on May 1, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Systemic Lupus Erythematosus
Additional conditions recognized in this trial
Lupus Erythematosus, Systemic
More general conditions related to this trial
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Interventions listed in this trial
Premarin and Provera
Additional drug interventions recognized in this trial
Estrogens
Estrogens, Conjugated (USP)
Hormones
Medroxyprogesterone Acetate
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Contraceptive Agents
Contraceptive Agents, Female
Contraceptive Agents, Male
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Sponsors listed in this trial
New York University School of Medicine
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Office of Research on Women's Health (ORWH)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services